SCYNEXIS (SCYX) Competitors $0.73 -0.01 (-1.38%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.78 +0.05 (+6.24%) As of 06/20/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. TARA, GNLX, BYSI, ANIX, CRDL, CCCC, CTNM, PLX, BHST, and HURAShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Protara Therapeutics (TARA), Genelux (GNLX), BeyondSpring (BYSI), Anixa Biosciences (ANIX), Cardiol Therapeutics (CRDL), C4 Therapeutics (CCCC), Contineum Therapeutics (CTNM), Protalix BioTherapeutics (PLX), BioHarvest Sciences (BHST), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Its Competitors Protara Therapeutics Genelux BeyondSpring Anixa Biosciences Cardiol Therapeutics C4 Therapeutics Contineum Therapeutics Protalix BioTherapeutics BioHarvest Sciences TuHURA Biosciences Protara Therapeutics (NASDAQ:TARA) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Does the MarketBeat Community believe in TARA or SCYX? SCYNEXIS received 463 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Protara Therapeutics an outperform vote while only 69.56% of users gave SCYNEXIS an outperform vote. CompanyUnderperformOutperformProtara TherapeuticsOutperform Votes4270.00% Underperform Votes1830.00% SCYNEXISOutperform Votes50569.56% Underperform Votes22130.44% Is TARA or SCYX more profitable? Protara Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. Protara Therapeutics' return on equity of -36.37% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.37% -33.29% SCYNEXIS -1,030.04%-53.47%-32.86% Which has higher earnings & valuation, TARA or SCYX? SCYNEXIS has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.72-1.77SCYNEXIS$3.75M7.64-$21.29M-$0.56-1.31 Do institutionals & insiders have more ownership in TARA or SCYX? 38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 12.5% of Protara Therapeutics shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor TARA or SCYX? In the previous week, Protara Therapeutics' average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score. Company Overall Sentiment Protara Therapeutics Neutral SCYNEXIS Neutral Do analysts recommend TARA or SCYX? Protara Therapeutics presently has a consensus target price of $20.50, indicating a potential upside of 572.13%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, TARA or SCYX? Protara Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. SummaryProtara Therapeutics and SCYNEXIS tied by winning 8 of the 16 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.65M$2.38B$5.18B$8.55BDividend YieldN/A1.56%5.38%4.21%P/E Ratio-1.318.7125.7219.14Price / Sales7.64488.87414.02109.91Price / CashN/A20.9925.4426.73Price / Book0.514.757.925.78Net Income-$21.29M$31.15M$3.15B$248.44M7 Day Performance-9.08%17.21%1.27%2.13%1 Month Performance-4.64%14.61%4.64%3.77%1 Year Performance-62.35%4.34%41.92%15.59% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.1696 of 5 stars$0.73-1.4%N/A-62.3%$28.65M$3.75M-1.3160TARAProtara Therapeutics1.8804 of 5 stars$3.17+1.0%$20.50+546.7%+35.0%$122.31MN/A-1.1230Positive NewsGNLXGenelux0.7219 of 5 stars$3.23+5.6%$17.75+449.5%+44.2%$121.88M$8K-3.4010High Trading VolumeBYSIBeyondSpringN/A$3.00+7.5%N/A+25.3%$120.95M$1.88M0.0080High Trading VolumeANIXAnixa Biosciences3.2252 of 5 stars$3.75+12.3%$9.00+140.0%+34.1%$120.79M$210K-9.625News CoverageGap UpHigh Trading VolumeCRDLCardiol Therapeutics2.4496 of 5 stars$1.43-2.1%$8.67+506.1%-33.0%$118.19MN/A-3.6720Positive NewsCCCCC4 Therapeutics1.7918 of 5 stars$1.63-3.0%$12.00+636.2%-66.5%$115.74M$39.78M-0.96150News CoveragePositive NewsCTNMContineum Therapeutics2.7597 of 5 stars$4.29-3.2%$22.50+424.5%-74.4%$114.61M$50M-2.1831News CoverageAnalyst ForecastPLXProtalix BioTherapeutics2.68 of 5 stars$1.43-4.0%$15.00+949.0%+19.7%$113.84M$59.76M-11.00200Gap UpBHSTBioHarvest SciencesN/A$6.84-5.0%$13.67+99.8%N/A$112.35M$27.70M-5.48N/AHURATuHURA Biosciences0.9491 of 5 stars$2.57+4.5%$12.67+392.9%N/A$112.26MN/A0.00N/AGap Up Related Companies and Tools Related Companies TARA Alternatives GNLX Alternatives BYSI Alternatives ANIX Alternatives CRDL Alternatives CCCC Alternatives CTNM Alternatives PLX Alternatives BHST Alternatives HURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 6/22/2025 by MarketBeat.com Staff From Our PartnersThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCYX Stock Free SCYX Stock Alerts